DK0444852T3 - Krystallinsk salt af 4-(di-n-propyl)amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenz(cd)indol - Google Patents

Krystallinsk salt af 4-(di-n-propyl)amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenz(cd)indol

Info

Publication number
DK0444852T3
DK0444852T3 DK91301501.2T DK91301501T DK0444852T3 DK 0444852 T3 DK0444852 T3 DK 0444852T3 DK 91301501 T DK91301501 T DK 91301501T DK 0444852 T3 DK0444852 T3 DK 0444852T3
Authority
DK
Denmark
Prior art keywords
tetrahydrobenz
aminocarbonyl
propyl
amino
indole
Prior art date
Application number
DK91301501.2T
Other languages
English (en)
Inventor
Thomas Joseph Kress
David Lee Varie
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0444852T3 publication Critical patent/DK0444852T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK91301501.2T 1990-02-26 1991-02-26 Krystallinsk salt af 4-(di-n-propyl)amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenz(cd)indol DK0444852T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48518590A 1990-02-26 1990-02-26

Publications (1)

Publication Number Publication Date
DK0444852T3 true DK0444852T3 (da) 1995-12-11

Family

ID=23927224

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91301501.2T DK0444852T3 (da) 1990-02-26 1991-02-26 Krystallinsk salt af 4-(di-n-propyl)amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenz(cd)indol

Country Status (28)

Country Link
US (1) US5397799A (da)
EP (1) EP0444852B1 (da)
JP (1) JP3157007B2 (da)
KR (1) KR100208114B1 (da)
CN (1) CN1027503C (da)
AT (1) ATE126506T1 (da)
AU (1) AU629453B2 (da)
BR (1) BR9100767A (da)
CA (1) CA2037099C (da)
CY (1) CY1887A (da)
DE (1) DE69112099T2 (da)
DK (1) DK0444852T3 (da)
ES (1) ES2077796T3 (da)
FI (1) FI95464C (da)
GR (1) GR3017940T3 (da)
HK (1) HK175495A (da)
HU (1) HU217118B (da)
IE (1) IE67801B1 (da)
IL (1) IL97306A (da)
LV (1) LV10251B (da)
NO (1) NO174149C (da)
NZ (1) NZ237181A (da)
PT (1) PT96852B (da)
RU (2) RU2034837C1 (da)
SG (1) SG69975A1 (da)
TW (1) TW219933B (da)
YU (1) YU47594B (da)
ZA (1) ZA911258B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302612A (en) * 1990-02-26 1994-04-12 Eli Lilly And Company 6-substituted-hexahydrobenz[cd]indoles
IL97309A (en) * 1990-02-26 1996-11-14 Lilly Co Eli Intermediates for hexahydrobenz] [DC indoles and a process for making their pure enantiomers
IL97308A (en) * 1990-02-26 1996-10-31 Lilly Co Eli Xahydrobenz [DC] Induced indoles in position 6, their preparation process and pharmaceutical preparations containing them
US5654324A (en) * 1991-03-28 1997-08-05 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2A,3,4,5-hexahydrobenz[cd]indoles
US5364856A (en) * 1991-03-28 1994-11-15 Eli Lilly And Company 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD]indoles
TW248556B (da) * 1993-01-18 1995-06-01 Takeda Pharm Industry Co
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
PL3357911T3 (pl) 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Inhibitory prolilohydroksylazy i sposoby ich użycia
NZ600405A (en) 2009-11-06 2014-08-29 Aerpio Therapeutics Inc Compositions and methods for treating colitis
EP3251671A1 (en) 2011-06-06 2017-12-06 Akebia Therapeutics Inc. Compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (da) 2011-06-06 2018-03-17
NZ753905A (en) 2013-06-13 2020-07-31 Akebia Therapeutics Inc Compositions and methods for treating anemia
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
BR112017015852A2 (pt) 2015-01-23 2018-03-27 Akebia Therapeutics Inc forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
IL292262B2 (en) 2015-04-01 2024-02-01 Akebia Therapeutics Inc Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid
TWI822776B (zh) 2018-05-09 2023-11-21 美商阿克比治療有限公司 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110339A (en) * 1977-11-25 1978-08-29 Eli Lilly And Company 4-(Di-n-propyl)amino-1,3,4,5-tetrahydrobenz[cd]indole
US4576959A (en) * 1984-02-06 1986-03-18 Eli Lilly And Company 6-Substituted-4-dialkylaminotetrahydrobenz[c,d]indoles
US4745126A (en) * 1987-03-12 1988-05-17 Eli Lilly And Company Method of treating anxiety with tetrahydrobenz[c,d]indole-6-carboxamides
DE3809155A1 (de) * 1988-03-18 1989-09-28 Bayer Ag 1,3,4,5-tetrahydrobenz-(c,d)-indole
US5204340A (en) * 1989-04-11 1993-04-20 Eli Lilly And Company Tetrahydrobenz(c,d)indole serotonin agonists
US5229409A (en) * 1990-08-15 1993-07-20 Eli Lilly And Company 6-substituted-tetrahydrobenz[cd]indoles

Also Published As

Publication number Publication date
HK175495A (en) 1995-11-24
AU7197191A (en) 1991-08-29
NO174149C (no) 1994-03-23
IE67801B1 (en) 1996-05-01
FI95464B (fi) 1995-10-31
ES2077796T3 (es) 1995-12-01
HU217118B (hu) 1999-11-29
RU2083561C1 (ru) 1997-07-10
KR910021375A (ko) 1991-12-20
AU629453B2 (en) 1992-10-01
JPH04217662A (ja) 1992-08-07
PT96852B (pt) 1998-07-31
IL97306A (en) 1996-10-16
EP0444852B1 (en) 1995-08-16
FI910895A0 (fi) 1991-02-25
YU32791A (sh) 1994-01-20
CA2037099C (en) 2001-09-11
DE69112099T2 (de) 1996-02-08
PT96852A (pt) 1991-10-31
RU2034837C1 (ru) 1995-05-10
FI910895A (fi) 1991-08-27
EP0444852A2 (en) 1991-09-04
ZA911258B (en) 1992-10-28
EP0444852A3 (en) 1992-02-19
ATE126506T1 (de) 1995-09-15
HUT56542A (en) 1991-09-30
CN1027503C (zh) 1995-01-25
NO910735D0 (no) 1991-02-25
NO174149B (no) 1993-12-13
FI95464C (fi) 1996-02-12
CA2037099A1 (en) 1991-08-27
SG69975A1 (en) 2000-01-25
NZ237181A (en) 1992-06-25
GR3017940T3 (en) 1996-02-29
JP3157007B2 (ja) 2001-04-16
LV10251A (lv) 1994-10-20
US5397799A (en) 1995-03-14
NO910735L (no) 1991-08-27
BR9100767A (pt) 1991-10-29
CY1887A (en) 1996-04-05
KR100208114B1 (ko) 1999-07-15
IE910625A1 (en) 1991-08-28
LV10251B (en) 1995-04-20
DE69112099D1 (de) 1995-09-21
IL97306A0 (en) 1992-05-25
TW219933B (da) 1994-02-01
CN1054589A (zh) 1991-09-18
YU47594B (sh) 1995-10-24

Similar Documents

Publication Publication Date Title
DK0444852T3 (da) Krystallinsk salt af 4-(di-n-propyl)amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenz(cd)indol
ES2123521T3 (es) Derivados de indol.
KR950700906A (ko) 5-ht1 작동약으로서의 인돌 유도체(indole derivatives as 5-ht1 agonists)
ATE180256T1 (de) 6-heterocyclisch-4-amino-1,3,4,5- tetrahydrobenz(cd>indole
RU92004575A (ru) Кристаллическая соль 4-(ди-н-пропил) амино-6-аминокарбонил-1,3,4,5-тетрагидробенз (cd) индола и ее 4p и 4s-изомеры
AU3427084A (en) (4,5-dihydro-1h-imidazo-z-yl)-1,2,4,5,6,7-hexa hydroazepino (3,2,1-hi) indole derivatives
ATE168687T1 (de) 6-heterocyclisch-4-amino-1,2,2a,3,4,5- hexahydrobenz(cd>indole
FI970397A0 (fi) Substituoituja 1,4-dihydroksylopent(b)indol-3(2H)-onijohdannaisia